Conferences - Results from #9440

ESMO 2017: Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases September 10, 2017

ESMO 2017: Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study September 10, 2017

ESMO 2017: Epithelial-mesenchymal transition, T cell infiltration, and outcomes with nivolumab in urothelial cancer September 10, 2017

ESMO 2017: Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial September 10, 2017

ESMO 2017: KEYNOTE-045: Pembrolizumab vs Individual Investigator’s Choice of Chemotherapy in Recurrent, Advanced Urothelial Cancer September 10, 2017

ESMO 2017: Impact of Tumor Mutation Burden on Nivolumab Efficacy in Second-Line Urothelial Carcinoma Patients: Exploratory Analysis of the Phase II CheckMate 275 Study September 10, 2017

ESMO 2017: ARASENS: A Phase 3 Trial of Darolutamide in Males with Metastatic Hormone-Sensitive Prostate Cancer September 10, 2017

ESMO 2017: Stereotactic Ablative Radiotherapy (SABR) for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) During Abiraterone Therapy: A Phase I Study September 10, 2017

ESMO 2017: Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) September 10, 2017

ESMO 2017: Phase I study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer September 10, 2017

ESMO 2017: Phase I, Open-label, Dose-Finding Study of GSK2636771, a phosphoinositide 3-kinase β inhibitor, in Combination with Enzalutamide in Male Subjects with Metastatic Castration-Resistant Prostate Cancer September 10, 2017

ESMO 2017: Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence enhancement and tumor inhibition in advanced prostate cancer September 10, 2017

ESMO 2017: Safety and Immunogenicity of a DNA-vaccine Immunotherapy in Men with Biochemically (PSA) Relapsed Prostate Cancer September 10, 2017

ESMO 2017: Abiraterone acetate + Prednisolone for metastatic Castration-Resistant Prostate Cancer (mCRPC) with early progression or non-response to Androgen Deprivation Therapy September 10, 2017

ESMO 2017: Randomized Controlled Trial Comparing Radiotherapy +/- Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG0401 September 10, 2017

ESMO 2017: Prognostic Associations of PSA Decline with Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide September 10, 2017

ESMO 2017: DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK September 10, 2017

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer September 10, 2017

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer September 10, 2017

ESMO 2017: Panel Discussion – Targeted Alpha Therapy September 9, 2017

Page 473 of 616